In the rapidly evolving treatment landscape for gynaecological cancers, five randomised Phase III trials of anti-PD-L1 agents in newly diagnosed or recurrent ovarian cancer have failed to demonstrate significantly improved outcomes in unselected populations, while offering hints of efficacy in patients with the highest PD-L1 expression [21–25]. This evidence concerns the gene CD274 and ovarian cancer.